Ki16198 is a potent and selective antagonist of the lysophosphatidic acid (LPA) receptors LPA1 and LPA3. It is primarily used in research settings to study and inhibit LPA-mediated signaling pathways involved in cellular processes such as proliferation, migration, survival, and fibrosis. This compound is particularly valuable in laboratory experiments exploring the roles of LPA signaling in diseases including cancer, inflammation, and fibrotic disorders. By blocking LPA1 and LPA3 receptors, Ki16198 enables researchers to investigate potential therapeutic strategies for conditions driven by dysregulated LPA signaling, contributing to the development of targeted treatments.